IL6 and COVID-19: In our study, the cytokines IL-6, IL-10, and TNF-α were significantly upregulated in severe COVID-19 patients, especially in male patients, indicating that IL-6 antagonists and TNF-α inhibitors are more appropriate used in male patients to reduce both severity and mortality rate of COVID-19.